Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1729-1736

  Ward, Richard L ^a   Kirkwood, Carl D ^b,d   Sander, Donna S ^a   Smith, Vicki E ^a   Shao, Mingyuan ^a   Bean, Judy A ^a   Sack, David A ^c,e   Bernstein, David I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Department of International Health   (United States)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e ICDDR B Centre for Health and Population Research   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOUBLE STRANDED RNA; MYLANTA; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE; ROTAVIRUS VACCINE 89 12; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; GASTROINTESTINAL INFECTION; GENE; HUMAN; INFANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAVIRUS; SEROTYPE; VACCINATION; VIRUS INFECTION; VP4 GENE; VP7 GENE;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MUTATION; NEUTRALIZATION TESTS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SERIAL PASSAGE; UNITED STATES; VACCINATION;

EID: 33845462577     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509623     Document Type: Article

References (43)

1. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6.
2. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973; 2:1281-3.
3. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8.
4. Clemens JD, Ward RL, Sack DA, et al. Seroepidemiological evaluation of anti-rotavirus antibodies as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. J Infect Dis 1992; 165:161-5.
5. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983; 309:72-6.
6. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282-7.
7. Fischer TK, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002; 186:593-7.
8. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991; 164:277-83.
9. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990; 162:1055-62.
10. Ward RL, Sander DS, Schiff GM, Bernstein DI. Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection. J Infect Dis 1990; 162:1298-303.
11. Ward RL, McNeal MM, Sander DS, Greenberg HB, Bernstein DI. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol 1993;67:464-8.
12. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16.
13. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-7.
14. Ward RL, Knowlton DR, Pierce MJ. Efficiency of human rotavirus propagation in cell culture. J Clin Microbiol 1984; 19:748-53.
15. Gilchrist MJ, Bretl TS, Moultney K, Knowlton DR, Ward RL. Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassay. Diagn Microbiol Infect Dis 1987;8:221-8.
16. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological responses to infection. J Infect Dis 1986; 154:871-80.
17. Ward KL, Bernstein DI, Shukla R, et al. Effects of antirotavirus antibody on protection of adults administered a human rotavirus. J Infect Dis 1989; 159:79-88.
18. Knowlton DR, Spector DM, Ward RL. Development of an improved method to measure neutralizing antibody titers to rotavirus. J Virol Methods 1991; 33:127-34.
19. Gentsch JR, Glass RI, Woods P, Gouvea M, Gorziglia J. Identification oi group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992; 30:1365-73.
20. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990; 28:276-82.
21. Isegawa Y, Nakagomi O, Nakagomi I, Ueda S. A VP4 sequence highly conserved in human rotavirus strain AU-1 and feline rotavirus strain FRV-1. J Gen Virol 1992; 73:1939-46.
22. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1984; 12:387-95.
23. Mason BB, Dheer SK, Hsiao CL, et al. Sequence of the serotype-specific glycoprotein of the human rotavirus Wa strain and comparison with other human rotavirus serotypes. Virus Res 1985; 2:291-9.
24. Gorziglia M, Green K, Nishikawa K, et al. Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections. J Virol 1988; 62:2978-84.
25. Kobayshi N, Taniguchi K, Urasawa S. Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4. J Gen Virol 1990; 71:2615-23.
26. Padialla-Noriega L, Dunn SJ, Lopez S, Greenberg HB, Arias CF. Identification of two independent neutralization domains on the VP4 trypsin cleavage products VP5* and VP8* of human rotavirus ST3. Virology 1995; 206:148-54.
27. Ward RL, Clark HF, Offit PA, Glass RI. Live vaccine strategies to prevent rotavirus disease. In: Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF, eds. New generation vaccines. 3rd ed. New York: Marcel Dekker, 2004:607-20.
28. Murphy TV, Gargiullo PM, Massoiudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72.
29. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
30. Green KY, Sarasini A, Qian Y, Gerna G. Genetic variation in rotavirus serotype 4 subtypes. Virology 1992; 188:362-8.
31. Gouvea V, Lima RCC, Linhares RE, Clark HF, Nosawa CM, Santos N. Identification of two lineages (WA-like and F45-like) within the major rotavirus genotype P[8]. Virus Res 1999; 59:141-7.
32. Hoshino Y, Jones RW, Ross J, et al. Rotavirus serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1 may be more suitable for serotype G9 vaccine candidates than those belonging to lineage 2 or 3. J Virol 2004; 78:7795-802.
33. Arista S, Giammanco GM, De Grazia S, Colomba C, Martella V. Genetic variability among serotype G4 Italian human rotaviruses. J Clin Microbiol 2005; 43:1420-5.
34. Kobayashi N, Taniguchi K, Urasawa T, Urasawa S. Analysis of the neutralizing epitopes on human rotavirus VP7 recognized by monotype-specific monoclonal antibodies. J Gen Virol 1991; 72:1855-61.
35. Coulson BS, Kirkwood C. Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype. J Virol 1991;65:5968-74.
36. Contreras JF, Menchaca GE, Padilla-Noriega L, et al. Heterogeneity of VP4 neutralization epitopes among serotype P1A human rotavirus strains. Clin Diagn Lab Immunol 1995;2:506-8.
37. Padilla-Noriega L, Mendez-Toss M, Menchaca G, et al. Antigenic and genomic diversity of human rotavirus VP4 in two consecutive-epidemic seasons in Mexico. J Clin Microbiol 1998; 36:1688-92.
38. Kirkwood C, Bogdanovic-Sakran N, Palombo E, et al. Genetic and antigenic characterization of rotavirus serotype G9 strains isolated in Australia between 1997 and 2001. J Clin Microbiol 2003; 41:3649-54.
39. Mota-Hernandez F, Calva JJ, Gutierrez-Camacho C, et al. Rotavirus diarrhea severity is related to the VP4 type in Mexican children. J Clin Microbiol 2003; 41:3158-62.
40. Mochizuki M, Nakagomi O. Two G3 feline rotavirus strains lacking cross-neutralization reactions represent distinct subtypes of serotype G3. Microbiol Immunol 1994; 38:229-32.
41. Piec TL, Palombo E. Sequence comparison of the VP7 of serotype G2 rotaviruses from diverse geographical locations. DNA Seq 1998; 9: 369-73.
42. Arista S, Giammanco G, De Grazia S, et al. G2 rotavirus infections in an infantile population of the south of Italy: variability of viral strains over time. J Med Virol 2005; 77:587-94.
43. Ruiz-Palacios G, Perez-Schael I, Velazquez F, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.